Klebsiella pneumoniae strains co-producing klebsiella pneumoniae carbapenemase (KPC) and verona integron-encoded metallo-betalactamase (VIM) are frequently isolated in Greece and have also occurred in other European countries. Conventional combined disc tests exhibit low sensitivity against these emerging pathogens.
Routine detection of carbapenemase-producing Klebsiella pneumoniae and other enterobacteria in the clinical laboratory is not included in the latest recommendations of CLSI [1] and EUCAST (www.eucast.org/clinical_breakpoints/). Nevertheless, application of reliable detection methods is essential in surveys performed to delineate the epidemiology of these pathogens and to control their spread [2, 3] . There are various carbapenemase-detecting methods grouped as phenotypic [based on the synergy between carbapenems and inhibitors of metallo-b-lactamases (MbLs), e.g. EDTA and dipicolinic acid, as well as boronates active against klebsiella pneumoniae carbapenemases (KPCs)], molecular (mainly PCR-based assays), and biochemical (e.g. determination of imipenem hydrolysis) [3, 4] .
Combined disc synergy tests have been extensively used because of their convenience and low cost. However, changes in carbapenemase-producing bacterial populations may compromise the performance of these assays. Previous studies have documented the spread of K. pneumoniae strains coproducing KPC and verona integron-encoded metallo-betalactamase (VIM) b-lactamases in Greek hospitals [5] [6] [7] [8] . It has been estimated that the double carbapenemase producers (DCPs) in this setting comprise approximately 5.5% of all carbapenemase-positive K. pneumoniae isolates [9] . Also, hospital infections caused by K. pneumoniae co-producing KPC and VIM or IMP b-lactamases have been described in Germany, Italy, China and Colombia [10] [11] [12] [13] [14] . Double carbapenemase producers may 'deceive' the conventional combined disc tests, frequently appearing negative for one or even both carbapenemases [5, 6, 12] .
We report here on two modifications (Methods A and B) of the KPC/MbL kit (ROSCO Diagnostica, Taastrup, Denmark) aiming to increase the reliability of DCP detection. The latter kit includes four tablets: meropenem (10 lg), meropenem + aminophenylboronic acid (600 lg), meropenem + dipicolinic acid (1000 lg) and meropenem + cloxacillin (750 lg) (www. rosco.dk) [15, 16] . In Method A, an additional tablet containing meropenem + aminophenylboronic acid + dipicolinic acid was included. Method B differed from Method A only in that phenylboronic acid (400 lg) was used instead of aminophenylboronic acid. Performance of Methods A and B was compared with that of the original KPC/MbL kit, as well as a recently described assay using four discs: meropenem, meropenem + phenylboronic acid, meropenem + EDTA and meropenem + phenylboronic acid + EDTA (Method C) [17] .
Methods were tested against a challenge set of 125 K. pneumoniae isolates from the collection of the Hellenic Pasteur Institute. Isolates had been characterized as described previously [5, 6, 18] . The set included 26 KPC-positive, 35 VIMpositive and 40 isolates positive for both VIM and KPC enzymes. The remaining isolates were OXA-48 plus extended spectrum b-lactamase (n = 5) and extended spectrum b-lactamase and/or AmpC producers (n = 19) ( Table 1 ). The range of imipenem and meropenem MICs for VIM and/or KPC carbapenemase-producing isolates as well as for the OXA-48-positive isolates was from 1 to >32 mg/L. The MIC 50 and MIC 90 values for both carbapenems were 32 and >32 mg/L, respectively. The respective values for carbapenemasenegative isolates (extended spectrum b-lactamase and/or AmpC producers) were significantly lower (MIC ranges for imipenem and meropenem were 1-2 and 0.5-8 mg/L, respectively). Twenty-one (80.89%) of the KPC producers were classified into sequence type 258 and the remaining were scattered into sequence types 133 (n = 2) and 383 (n = 3). The VIM-positive isolates as well as DCPs were distributed into sequence types 147 (n = 56, 22 DCPs), 323 (n = 5, 5 DCPs), 383 (n = 12, 12 DCPs) and 945 (n = 2, 1 DCP).
The algorithm used to interpret results obtained by Methods A and B is described in Fig. 1 . An isolate was classified as KPCpositive when aminophenylboronic acid or phenylboronic acid caused a >4 mm increase in the inhibitory zone diameter of meropenem. A difference of >5 mm between the inhibitory zone diameters around discs containing meropenem + dipicolinic acid and meropenem alone indicated MbL production. To facilitate detection of DCPs, inhibition by the meropenem + dipicolinic acid + aminophenylboronic acid/phenylboronic acid discs was considered for all isolates appearing positive for either carbapenemase type or negative for both. Hence, a >4-mm difference in inhibition zone by the 'triple' disc compared with meropenem + dipicolinic acid was regarded as indicative of KPC production. Also, a similar inhibition zone difference between the 'triple' and meropenem + aminophenylboronic acid/phenylboronic acid discs indicated MbL production. In cases of negative results with both 'double' discs as well as the 'triple' disc, other carbapenem-resistance mechanisms, most importantly ΟΧΑ-48 production, must be considered.
Results are summarized in Table 1 . The KPC/MbL kit, as well as Methods A, B and C exhibited excellent specificity; false positives among the isolates lacking either VIM or KPC carbapenemases and possessing AmpC and/or extended spectrum b-lactamase producers) were not observed. However, one out of the five OXA-48-positive isolates was falsely classified as an MbL producer. Also, all four methods performed well against the 61 single carbapenemase producers. The KPC/ MbL kit and Method A failed to detect carbapenemase in three KPC producers whereas Method B correctly classified all but one single carbapenemase producer. Method C misclassified a KPC-positive isolate as a producer of both carbapenemase types. Significant problems, however, were encountered with the subset of the 40 DCPs. The lowest sensitivity was observed with the KPC/MbL kit, which missed 32 DCPs. Method A displayed low sensitivity-detecting production of both carbapenemase types in only 22 of these isolates. Sensitivity was dramatically improved by replacing aminophenylboronic acid with phenylboronic acid. Indeed, Method B correctly classified 39 DCPs. Most of the DCPs misclassified by the above assays appeared as MbL producers. The performance of Method C was comparable with that of Method A.
It has been shown previously that phenylboronic acid is more effective than aminophenylboronic acid in detecting KPC producers by boronate-based combined disc assays [19] . Hence, the better diagnostic value of Method B over Method A against DCPs can be attributed to the use of phenylboronic acid instead of aminophenylboronic acid. Apparently, phenylboronic acid reduced the masking effect of the simultaneously produced VIM more efficiently than aminophenylboronic acid. We did not systematically pursue the sources of DCP classification errors of Method C. Specificity problems caused by EDTA, as reported previously [15] , were not observed, probably because relatively low amounts of the inhibitor were used [17] . Yet, the proposed algorithm in Method C implies a questionable term that may partly explain DCP misclassifications: results of the meropenem + phenylboronic acid + EDTA-containing discs were taken into account only in K. pneumoniae isolates that were found to be negative for both carbapenemase types by the respective meropenem + single inhibitor discs [17] . Apparently, in Method C, the fact that a DCP may appear as a single carbapenemase producer was overlooked.
The main limitation of this study is that it includes isolates from a single enterobacterial species, K. pneumoniae, carrying only two carbapenemase types, KPC and VIM. Yet, the proposed modification (Method B) of the KPC/MbL kit resulted in a clear improvement in detection of the emerging group of double carabapenemase-producing K. pneumoniae.
